Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?Zacks Investment Research • 10/29/24
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program CommitteesGlobeNewsWire • 10/21/24
Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024GlobeNewsWire • 10/15/24
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?Zacks Investment Research • 10/08/24
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the BoardBusiness Wire • 10/08/24
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni AwardGlobeNewsWire • 09/19/24
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/27/24
Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 07/30/24
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine StrategyGlobeNewsWire • 06/10/24
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesGlobeNewsWire • 06/04/24
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory BoardGlobeNewsWire • 05/30/24
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketGlobeNewsWire • 04/22/24
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main MarketGlobeNewsWire • 04/11/24